Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21195168 | 0.83 | KMT2A (0.35) | — | |
| SCHEMBL15106318 | 0.83 | CYP1A2 (0.39) | — | |
| SCHEMBL8398612 | 0.83 | CYP1A2 (0.39) | — | |
| SCHEMBL28666508 | 0.83 | IDO1 (0.34) | — | |
| SCHEMBL28666510 | 0.83 | IDO1 (0.34) | — | |
| SCHEMBL6389450 | 0.82 | KIF11 (0.39) | KIF11DNMT1 | |
| SCHEMBL1491452 | 0.80 | CYP1A2 (0.34) | KIF11 | |
| SCHEMBL13583914 | 0.80 | ITGA4 (0.32) | — | |
| SCHEMBL7338794 | 0.78 | ITGA4 (0.39) | — | |
| SCHEMBL7107498 | 0.77 | PTPRC (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GIMI RAYOMAND H | 2006-12-14 | — | — | US | disclosed |
| US-7115769-B2 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1529037-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | Genzyme Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| WO-2003097622-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | KIF11 4699/4885SIRT2 1652/4885DNMT1 1291/4885 |
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | KIF11 4699/4885SIRT2 1652/4885DNMT1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.